{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=5&q=castration-resistant", "query": { "q": "castration-resistant", "condition": "Prostate Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 745, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=6&q=castration-resistant&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer&page=4&q=castration-resistant&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T03:31:05.146Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05751941", "title": "Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Metastatic Prostate Cancer" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Sipuleucel-T", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 26, "start_date": "2023-02-14", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 2, "location_summary": "Tampa, Florida • Columbus, Ohio", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05751941" }, { "nct_id": "NCT06609005", "title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "INV-9956", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shenzhen Ionova Life Sciences Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 84, "start_date": "2025-01-23", "completion_date": "2028-01-17", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Newport Beach, California • Orange, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06609005" }, { "nct_id": "NCT03009981", "title": "A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Apalutamide", "type": "DRUG" }, { "name": "LHRH Analogue", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 504, "start_date": "2017-03-06", "completion_date": "2025-06-25", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 69, "location_summary": "Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03009981" }, { "nct_id": "NCT01240629", "title": "Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "doxorubicin-GnRH agonist conjugate AEZS-108", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 43, "start_date": "2010-11-02", "completion_date": "2017-02-02", "has_results": false, "last_update_posted_date": "2017-07-11", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01240629" }, { "nct_id": "NCT04868604", "title": "64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "64Cu-SAR-bisPSMA", "type": "DRUG" }, { "name": "67Cu-SAR-bisPSMA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clarity Pharmaceuticals Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 54, "start_date": "2021-08-11", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 7, "location_summary": "Stanford, California • River Ridge, Louisiana • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "River Ridge", "state": "Louisiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04868604" }, { "nct_id": "NCT05022849", "title": "A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "JNJ-75229414", "type": "DRUG" }, { "name": "Bridging Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 15, "start_date": "2021-09-28", "completion_date": "2026-03-11", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 8, "location_summary": "Duarte, California • Louisville, Kentucky • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05022849" }, { "nct_id": "NCT04577833", "title": "A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Abiraterone Acetate (AA)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 136, "start_date": "2020-11-13", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 1, "location_summary": "West Valley City, Utah", "locations": [ { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04577833" }, { "nct_id": "NCT04104893", "title": "A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2020-02-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 13, "location_summary": "San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104893" }, { "nct_id": "NCT05177770", "title": "Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "SRF617", "type": "DRUG" }, { "name": "etrumadenant", "type": "DRUG" }, { "name": "zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2022-01-17", "completion_date": "2023-04-05", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 7, "location_summary": "Miami, Florida • Ann Arbor, Michigan • Las Vegas, Nevada + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05177770" }, { "nct_id": "NCT07540572", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ER+, HER 2- Breast Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Castration-resistant Prostate Cancer (CRPC)", "Microsatellite Stable (MSS) Colorectal Carcinoma" ], "interventions": [ { "name": "IDE574", "type": "DRUG" }, { "name": "Fulvestrant injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 160, "start_date": "2026-03-17", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-08T03:31:05.146Z", "location_count": 11, "location_summary": "Plantation, Florida • East Brunswick, New Jersey • Lake Success, New York + 7 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Lake Success", "state": "New York" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07540572" } ] }